Company Filing History:
Years Active: 1997
Title: Pierre Henkart: Innovator in HIV Research
Introduction
Pierre Henkart is a notable inventor based in Annapolis, MD (US). He has made significant contributions to the field of HIV research, particularly in understanding programmed cell death in T lymphocytes infected with HIV-1. His work has implications for therapeutic interventions that can restore immune function in affected individuals.
Latest Patents
Henkart holds a patent titled "In vitro methods for assessing the susceptibility of HIV-1-infected." This patent highlights the role of calpain as a component of the biochemical pathway in programmed cell death. Calpain inhibitors have been identified as effective agents in preventing the progression to cell death and restoring cell function. The methods outlined in his patent provide a means for diagnosing cell populations or individuals susceptible to programmed cell death and for monitoring therapeutic effectiveness.
Career Highlights
Pierre Henkart is associated with the United States of America as represented by the Department of Health. His research has been pivotal in advancing the understanding of HIV-1 infection and its effects on T lymphocytes. His innovative approaches have opened new avenues for treatment and diagnosis in the field of immunology.
Collaborations
Henkart has collaborated with notable colleagues such as Apurva Sarin and Mario S Clerici. Their combined expertise has contributed to the advancement of research in HIV and immune response.
Conclusion
Pierre Henkart's work exemplifies the critical intersection of innovation and healthcare. His contributions to HIV research through his patent and collaborations have the potential to significantly impact therapeutic strategies for infected individuals.